38 min
#052 Digital Twins in Clinical Trials — Dr Charles Fisher (CEO Unlearn.ai) Big Picture Medicine
-
- Medicine
How can you use digital twins for faster clinical trials requiring fewer patients?
Dr Charles Fisher is the CEO and Founder of Unlearn.ai — which uses digital twins to reduce the number of patients required in clinical trials.
In a clinical trial, you usually have a treatment group who receive the drug/treatment, and a control group who receive a placebo. This means that a large number of patients need to be given a placebo — a fake or dummy version of the treatment with no therapeutic effect.
But using generative machine learning models, you can create a digital twin — a digital copy of a patient which might be able to emulate what would have happened to that patient if they’d received a placebo.
The promise of this technology is faster clinical trials, requiring fewer patients and producing better evidence.
Charles completed his PhD in Biophysics at Harvard and has raised $17M to date for Unlearn.ai. We talk about digital twins, viewing clinical trials with a biophysics lens and some of the challenges in getting this technology adopted.
I hope you enjoy.
You can find me on Twitter @MustafaSultan and subscribe to my newsletter on www.musty.io
How can you use digital twins for faster clinical trials requiring fewer patients?
Dr Charles Fisher is the CEO and Founder of Unlearn.ai — which uses digital twins to reduce the number of patients required in clinical trials.
In a clinical trial, you usually have a treatment group who receive the drug/treatment, and a control group who receive a placebo. This means that a large number of patients need to be given a placebo — a fake or dummy version of the treatment with no therapeutic effect.
But using generative machine learning models, you can create a digital twin — a digital copy of a patient which might be able to emulate what would have happened to that patient if they’d received a placebo.
The promise of this technology is faster clinical trials, requiring fewer patients and producing better evidence.
Charles completed his PhD in Biophysics at Harvard and has raised $17M to date for Unlearn.ai. We talk about digital twins, viewing clinical trials with a biophysics lens and some of the challenges in getting this technology adopted.
I hope you enjoy.
You can find me on Twitter @MustafaSultan and subscribe to my newsletter on www.musty.io
38 min